We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Legend Biotech
LEGN
$4.01B
| $4.21M | ﹤0.01% |
103,271
+6,700
| +7% | +$314K |
|
1977
Celldex Therapeutics
CLDX
$3.28B
| $4.21M | ﹤0.01% |
149,646
-4,324
| -3% | -$133K |
|
1978
First Commonwealth Financial
FCF
$2.17B
| $4.21M | ﹤0.01% |
327,557
-9,562
| -3% | -$134K |
|
1979
QuantumScape Corp
QS
$3.74B
| $4.21M | ﹤0.01% |
500,029
-14,596
| -3% | -$157K |
|
1980
CryoPort
CYRX
$762M
| $4.2M | ﹤0.01% |
172,282
-8,718
| -5% | -$300K |
|
1981
Opko Health
OPK
$1.02B
| $4.16M | ﹤0.01% |
2,201,636
-483,570
| -18% | -$1.14M |
|
1982
Kelly Services Class A
KELYA
$528M
| $4.15M | ﹤0.01% |
305,287
-17,017
| -5% | -$307K |
|
1983
Plains GP Holdings
PAGP
$4.9B
| $4.15M | ﹤0.01% |
380,236
+137,830
| +57% | +$1.58M |
|
|
TSE
1984
DELISTED
Trinseo
TSE
| $4.14M | ﹤0.01% |
226,115
-4,577
| -2% | -$143K |
|
1985
Granite Construction
GVA
$5.62B
| $4.13M | ﹤0.01% |
162,846
-6,662
| -4% | -$196K |
|
1986
Scansource
SCSC
$1.12B
| $4.13M | ﹤0.01% |
156,299
+6,518
| +4% | +$197K |
|
1987
Hanmi Financial
HAFC
$946M
| $4.12M | ﹤0.01% |
173,897
-6,972
| -4% | -$171K |
|
|
CCC
1988
CCC Intelligent Solutions
CCC
$4.08B
| $4.11M | ﹤0.01% |
451,104
+120,964
| +37% | +$1.14M |
|
1989
Triumph Financial Inc
TFIN
$1.82B
| $4.1M | ﹤0.01% |
75,459
-1,939
| -3% | -$128K |
|
1990
Expro Ltd
XPRO
$1.91B
| $4.09M | ﹤0.01% |
321,218
-5,533
| -2% | -$67.1K |
|
1991
Krispy Kreme
DNUT
$577M
| $4.08M | ﹤0.01% |
353,782
-234,971
| -40% | -$3.09M |
|
1992
Veru
VERU
$37.4M
| $4.08M | ﹤0.01% |
35,379
-4,881
| -12% | -$704K |
|
1993
Interparfums
IPAR
$3.94B
| $4.07M | ﹤0.01% |
53,936
-1,709
| -3% | -$135K |
|
1994
Certara
CERT
$1.25B
| $4.06M | ﹤0.01% |
305,631
-18,288
| -6% | -$338K |
|
|
GTY
1995
Getty Realty Corp
GTY
$2.07B
| $4.03M | ﹤0.01% |
150,013
-5,817
| -4% | -$167K |
|
1996
Nuveen ESG Dividend ETF
NUDV
$51.1M
| $4.03M | ﹤0.01% |
190,100
| – | – |
|
1997
B&G Foods
BGS
$286M
| $4.03M | ﹤0.01% |
244,343
-148,357
| -38% | -$3.29M |
|
1998
TechnipFMC
FTI
$27.3B
| $4.03M | ﹤0.01% |
475,940
-13,460
| -3% | -$106K |
|
1999
AdvanSix
ASIX
$444M
| $4.02M | ﹤0.01% |
125,274
-120,084
| -49% | -$4.32M |
|
|
FMTX
2000
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $4.01M | ﹤0.01% |
200,901
-13,458
| -6% | -$177K |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.